肺癌
间变性淋巴瘤激酶
医学
肿瘤科
内科学
临床试验
癌症
恶性胸腔积液
作者
Yafeng Liu,Zhibin Han,Yujia Li,Pengfei Zhang,Qiushi Wang
标识
DOI:10.3389/fphar.2025.1665174
摘要
This study provides a comprehensive bibliometric analysis and summary of the developmental trajectory, current research landscape, and future trends in ALK-TKI therapy for NSCLC over the past decade, with individualized and precision medicine remaining the primary direction for the development of ALK-TKI therapy in NSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI